Fusidic acid Raw Materials Powder

CAS:6990-06-3

MF: C31H48O6

MW: 516.72

EINECS: 230-256-0

Specification​: 99% min Fusidic acid Powder

Sample: Fusidic acid Powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Fusidic acid Powder Usage and Synthesis.

Fusidic acid oral suspension/fusidic acid sodium for injection:

For use in a variety of infections caused by various sensitive bacteria, especially staphylococci, such as osteomyelitis, sepsis, endocarditis, recurrent infections of cystic fibrosis, pneumonia, skin and soft tissue infections, surgical and traumatic infections.

Fusidic acid cream:

Used for skin infections caused by Staphylococcus, Streptococcus, Propionibacterium acnes, Corynebacterium minutum and other fusidic acid-sensitive bacteria. The main indications include: impetigo, boils, carbuncles, onychomycosis, traumatic infections, beard sores, sweat infections, erysipelas, folliculitis, and acne vulgaris. It is indicated for infections of the face and head and other areas without external obstruction.

Fusidic acid eye drops: for acute bacterial conjunctivitis.

Clinically fusidic acid is used for osteomyelitis or skin and soft tissue infections caused by sensitive bacteria. It is also used for deep infections where other antibiotic treatments have failed, such as sepsis, pneumonia and endocarditis. Adults: oral, 500 mg once, tid; double for severe cases. Topical administration, bid ~ tid, applied to the affected area, the course of treatment is 7 days. Treatment of scabies can be extended according to the needs of the condition. Children: oral, for children under 1 year old 50mg/kg a day, divided into three times; for children 1 ~ 5 years old 250mg a time, tid; for children 5 ~ 12 years old, the dosage is the same as adults.

Uses and functions of Fusidic acid Raw Powder.

Clinical application is usually made into sodium salt, the molecular formula of sodium salt is C31H47NaO6. fusidic acid is highly sensitive to all kinds of Gram-positive cocci associated with skin infections, especially staphylococci, and is also effective against drug-resistant Staphylococcus aureus, and also has a certain degree of antimicrobial effect on some Gram-negative bacteria. No cross resistance with other antibiotics

Pharmacological Effects of Fusidic acid Raw Materials Powder.

1. Fucidin®systemic has occasionally been reported to potentiate the anticoagulant effects of coumarin derivatives or other anticoagulant drugs, and the anticoagulant effects can be controlled at a defined level by adjusting the oral dose. Fucidin®systemic should be avoided in patients with CYP-3A4 biotransformation drugs.

2. The combination of Fucidin®systemic with HMG-CoA reductase inhibitors such as statins can lead to increased plasma concentrations of both drugs, resulting in increased creatine kinase levels (rhabdomyolysis), muscle weakness and pain.

3. The combination of Fucidin®systemic with HIV protease inhibitors such as ritonavir and saquinavir can result in elevated plasma concentrations of both drugs and may cause hepatotoxicity. Elevated plasma concentrations of cyclosporine have been reported with Fucidin®systemic in combination with cyclosporin.

Production method of Fusidic acid Raw.

1, Fusidic acid produces antibacterial effect by inhibiting the protein synthesis of bacteria.

2, Fusidic acid has strong antibacterial effect on a variety of Gram-positive bacteria. Staphylococci, including strains resistant to penicillin, methicillin and other antimicrobial agents, are highly sensitive to this product.

There is no cross-resistance between this product and other antibacterial drugs used in clinical practice.

4, the toxicity of this product is very low, and there is no cross-allergy between this product and other antibacterial drugs used in the clinic, so this product can be used for the treatment of other antibacterial contraindications, such as penicillin or other antibacterial drugs allergic to patients and patients with renal function impairment.